Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JBT-101 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| JBT101 (lenabasum) 1 mg | EXPERIMENTAL | JBT-101 1 mg once a day on Days 1-28 |
| JBT-101 (lenabasum) 5 mg | EXPERIMENTAL | JBT-101 5 mg once a day on Days 1-28 |
| Placebo | PLACEBO_COMPARATOR | Placebo once a day on Days 1-28. |
| JBT-101 (lenabasum) 20 mg QD | EXPERIMENTAL | JBT-101 20 mg once a day on Days 29-84. |
| JBT-101 (lenabasum) 20 mg BID | EXPERIMENTAL | JBT-101 20 mg twice daily on Days 29-84. |
| Placebo BID | PLACEBO_COMPARATOR | Placebo twice daily on Days 29-84. |
| Name | Type | Description |
|---|---|---|
| JBT-101 (lenabasum) | DRUG | Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84. |
| Placebo | OTHER | Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84. |
Inclusion Criteria: * Documentation of a CF diagnosis as evidenced by 1 or more clinical features consistent with the CF phenotype and 1 or more of the following criteria: 1. Sweat chloride equal to or greater than 60 mEq/L by quantitative pilocarpine iontophoresis test; 2. Two well-characteri...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | VRTX | 8 | PHASE3 | VX-121/TEZ/D-IVA |
| Sionna Therapeutics, Inc. | SION | 2 | PHASE2 | SION-719 |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| 4D Molecular Therapeutics, Inc. | FDMT | 1 | PHASE2 | 4D-710 |
| Arcturus Therapeutics Holdings, Inc. | ARCT | 1 | PHASE2 | ARCT-032 |
| Krystal Biotech, Inc. | KRYS | 1 | PHASE1 | KB407 |
| Illumina, Inc. | ILMN | 1 | - | Undisclosed |
JBT-101 is an investigational small molecule being studied for the treatment of Cystic Fibrosis. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being evaluated for its safety, tolerability, pharmacokinetics, and efficacy in patients with this condition.
JBT-101 is being developed by Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol CRBP. The company is conducting clinical trials to evaluate the drug's potential in treating Cystic Fibrosis.
JBT-101 is in Phase 2 clinical development for Cystic Fibrosis. It is an investigational drug, meaning it has not yet received regulatory approval and is still being studied in clinical trials to assess its safety and efficacy.
JBT-101 has been studied in one completed Phase 2 clinical trial with the identifier NCT02465450. This randomized, double-blind, placebo-controlled trial enrolled 85 participants aged 18 years and older with Cystic Fibrosis, and was conducted across multiple countries including the United States, Belgium, France, Germany, Italy, Poland, and the United Kingdom.
Yes, JBT-101 is also known as Lenabasum. The Phase 2 clinical trial NCT02465450, which evaluated the drug in Cystic Fibrosis, is titled 'Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis,' confirming that both names refer to the same investigational drug.